Yposkesi welcomes Patrick Lansky as VP of US sales & marketing
With 20 years’ biotech experience including a decade in CDMO cell and gene therapy, Mr. Lanksy is charged with forging bioprocessing partnerships with US biopharmaceuticals developers
Corbeil-Essonnes, France, February 24,…
Yposkesi’s clinical batches of G1XCGD lentiviral vector used in rare immune system disease study
International research team published initial clinical trial results in Nature Medicine of nine X-Linked Chronic Granulomatous Disease (CGD) patients
Corbeil-Essonnes, France, January 29, 2019 – Yposkesi,…
Yposkesi selected to produce clinical and large-scale commercial material of micro-dystrophin for Genethon and Sarepta Therapeutics program
Yposkesi selected to produce clinical and large-scale commercial material of micro-dystrophin for Genethon and Sarepta Therapeutics program
Its capacity to produce AAV (Adeno Associated Virus) materials at large-scale…
Yposkesi sélectionné pour la Grande Exposition du Fabriqué en France à l’Elysée les 18 et 19 janvier 2020
L’entreprise y présentera au grand public ses candidats-médicaments de thérapie génique pour les maladies rares
Corbeil-Essonnes, France, le 15 janvier 2020 – Yposkesi, un CDMO…